AUSTIN, Texas–(BUSINESS WIRE)–PanTher Therapeutics (“PanTher” or the “Company”), a clinical-stage company redefining cancer treatment with therapeutics administered continuously and exclusively at the tumor site, today announced that the first patient has been treated with PTM-101 in a Phase 1b clinical trial in pancreatic ductal adenocarcinoma (PDAC). PTM-101 is the most advanced product candidate within PanTher’s portfolio of innovative formulations for continuous, high-dose, localized drug administration directly to the site of the tumor.
PanTher Therapeutics Initiates Phase 1b clinical trial of absorbable, long-lasting, high-dose chemotherapy patch for pancreatic cancer
